Story
Eli Lilly's Oral Weight-Loss Drug Foundayo Gains First European Approval in UK

Eli Lilly's (NYSE: LLY) oral medication Foundayo has been authorized for weight management and type 2 diabetes by Britain’s medicines regulator, making the UK the first European country to approve the treatment. The news boosted the company's shares, which were up more than 3% in afternoon trading on Monday.
UK Authorization and Launch
The Medicines and Healthcare products Regulatory Agency (MHRA) confirmed the approval but noted the drug's immediate availability is limited. "Whilst this tablet is approved for use in the UK, it is not available currently via the NHS," the agency stated.
According to a company spokesperson who spoke to Reuters, Eli Lilly plans to launch Foundayo in the UK later this month through private prescription. The spokesperson added that the pill's private list price would be lower than its injectable drug Mounjaro, which costs £399 for a month's supply, but did not provide specific pricing details.
AdCompetitive Landscape
The approval intensifies the competition between Eli Lilly and rival Novo Nordisk (NYSE: NVO) in the rapidly growing market for weight-loss therapies, which is increasingly expanding from injectable treatments to oral alternatives. While injectables still dominate the market, pills are gaining significant traction among patients.
Foundayo, a once-daily GLP-1 tablet, holds a key convenience advantage over its primary oral competitor. According to the report, Foundayo can be taken without restrictions on food or water. This contrasts with Novo Nordisk's Wegovy pill, which requires patients to take it on an empty stomach and wait 30 minutes before consuming food, beverages, or other medications.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.